Literature DB >> 11274767

Combining G-CSF with a blockade of adhesion strongly improves the reconstitutive capacity of mobilized hematopoietic progenitor cells.

O Christ1, R Kronenwett, R Haas, M Zöller.   

Abstract

OBJECTIVE: Mobilization of hematopoietic progenitor cells is achieved mainly by application of growth factors and, more recently, by blockade of adhesion. In this report, we describe the advantages of a combined treatment with granulocyte colony-stimulating factor (G-CSF) and anti-VLA4 (CD49d)/anti-CD44 as compared to treatment with the individual components.
MATERIALS AND METHODS: Mobilization by intravenous injection of anti-CD44, anti-VLA4, or G-CSF was controlled in spleen and bone marrow with regard to frequencies of multipotential colony-forming unit (C-CFU), marrow repopulating ability, long-term reconstitution, recovery of myelopoiesis, and regain of immunocompetence.
RESULTS: Mobilization by anti-CD44 had a strong effect on expansion of early progenitor cells in the bone marrow, while the recovery in the spleen was poor. In anti-CD49d-mobilized noncommitted and committed progenitors, progenitor expansion was less pronounced, but settlement in the spleen was quite efficient. Thus, anti-CD44 and anti-CD49d differently influenced mobilization. Accordingly, mobilization and recovery after transfer were improved by combining anti-CD44 with anti-CD49d treatment. Mobilization by G-CSF was most efficient with respect to recovery of progenitor cells in the spleen. However, when transferring G-CSF-mobilized cells, regain of immunocompetence was strongly delayed. This disadvantage could be overridden when progenitor cells were mobilized via blockade of adhesion and when expansion of these mobilized progenitor cells was supported by low-dose G-CSF only during the last 24 hours before transfer.
CONCLUSION: Mobilization of pluripotent progenitor cells via antibody blockade of CD44 or CD49d or via G-CSF relies on distinct mechanisms. Therefore, the reconstitutive capacity of a transplant can be significantly improved by mobilization regimens combining antibody with low-dose G-CSF treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274767     DOI: 10.1016/s0301-472x(00)00674-3

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

1.  Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPC.

Authors:  Halvard Bonig; Gregory V Priestley; Vivian Oehler; Thalia Papayannopoulou
Journal:  Exp Hematol       Date:  2007-02       Impact factor: 3.084

Review 2.  The biology of CD44 and HCELL in hematopoiesis: the 'step 2-bypass pathway' and other emerging perspectives.

Authors:  Robert Sackstein
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

Review 3.  Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

Authors:  Clemens Warnke; Til Menge; Hans-Peter Hartung; Michael K Racke; Petra D Cravens; Jeffrey L Bennett; Elliot M Frohman; Benjamin M Greenberg; Scott S Zamvil; Ralf Gold; Bernhard Hemmer; Bernd C Kieseier; Olaf Stüve
Journal:  Arch Neurol       Date:  2010-08

4.  MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization.

Authors:  Yaron Vagima; Abraham Avigdor; Polina Goichberg; Shoham Shivtiel; Melania Tesio; Alexander Kalinkovich; Karin Golan; Ayelet Dar; Orit Kollet; Isabelle Petit; Orly Perl; Ester Rosenthal; Igor Resnick; Izhar Hardan; Yechiel N Gellman; David Naor; Arnon Nagler; Tsvee Lapidot
Journal:  J Clin Invest       Date:  2009-02-09       Impact factor: 14.808

Review 5.  CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells.

Authors:  Margot Zöller
Journal:  Front Immunol       Date:  2015-05-26       Impact factor: 7.561

6.  CD44 standard and CD44v10 isoform expression on leukemia cells distinctly influences niche embedding of hematopoietic stem cells.

Authors:  Ulrike Erb; Amelie Pajip Megaptche; Xiaoyu Gu; Markus W Büchler; Margot Zöller
Journal:  J Hematol Oncol       Date:  2014-03-31       Impact factor: 17.388

7.  The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.

Authors:  Tamara Girbl; Verena Lunzer; Richard Greil; Konrad Namberger; Tanja Nicole Hartmann
Journal:  Transfusion       Date:  2014-03-28       Impact factor: 3.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.